Could some AML patients stop treatment early? new study investigates

NCT ID NCT06557421

First seen Mar 31, 2026 · Last updated May 15, 2026 · Updated 6 times

Summary

This study looks at whether people with acute myeloid leukemia (AML) who have done well on a combination of venetoclax and azacitidine can safely stop taking these drugs. About 50 participants who have been on treatment for 12 months and are in remission will stop their medication and be closely monitored. The goal is to see if stopping treatment affects how long they stay cancer-free, compared to similar patients who continued therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institut Paoli-Calmettes

    RECRUITING

    Marseille, 13273, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.